Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte has developeda series of novel compounds that inhibit the growth of common brain cancers ofadults and children in mouse models. We have now found that some variants ofthese compounds have effects on brain cells that are believed to bepotentially useful for the treatment of common neurodegenerative braindiseases. Since Lixte is focused primarily on developing anti-cancer drugs,we are exploring partnerships with companies that have expertise and researchprograms in the treatment of Alzheimer's Disease."
About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics anddiagnostics company. Founded as a biomarker-diagnostics company in 2005,Lixte develops new chemotherapy drugs targeting molecular abnormalities ofcommon human cancers.
This announcement contains certain forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, and Section 21E of theSecurities Exchange Act of 1934. For example, statements regarding theCompany's financial position, business strategy and other plans and objectivesfor future operations, and assumptions and predictions about future productdemand, supply, manufacturing, costs, marketing and pricing factors are allforward-looking statements. These statements are generally accompanied bywords such as "intend," anticipate," "believe," "estimate," "potential(ly),""continue," "forecast," "predict," "plan," "may," "will," "could," "would,""should," "expect" or the negative of such terms or other comparableterminology. The Company believes that the assumptions and expectationsreflected in such forward-looking statements are reasonable, based oninformation available to it on the date hereof, but the Company cannot provideassurances that these assumptions and expectations will prove to have beencorrect or that the Company will take any action that the Company maypresently be planning. However, these forward-looking statements areinherently subject to known and unknown risks and uncertainties. Actualresults or experience may differ materially from those expected or anticipatedin the forward-looking statements. Factors that could cause or contribute tosuch differences include, but are not limited to, regulatory policies,available cash, research results, competition from other similar businesses,and market and general economic factors. This discussion should be read inconjunction with the condensed consolidated financial statements and notesthereto included on Form 10-QSB for the quarter ending June 30, 2008.Please see our Website: www.Lixte.com For Investor Information, please contact: Frank Benedetto Mirador Consulting, Inc. 561-989-3600
SOURCE Lixte Biotechnology Holdings, Inc.
You May Also Like